Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
25.87
+1.20 (4.86%)
At close: Jun 26, 2026, 4:00 PM EDT
26.99
+1.12 (4.33%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Zenas BioPharma Employees
Zenas BioPharma had 167 employees as of December 31, 2025. The number of employees increased by 37 or 28.46% compared to the previous year.
Employees
167
Change (1Y)
37
Growth (1Y)
28.46%
Revenue / Employee
n/a
Profits / Employee
-$2,545,814
Market Cap
1.63B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 167 | 37 | 28.46% |
| Dec 31, 2024 | 130 | 23 | 21.50% |
| Sep 30, 2024 | 115 | 31 | 36.90% |
| Jun 30, 2024 | 114 | 30 | 35.71% |
| Mar 31, 2024 | 107 | - | - |
| Sep 30, 2023 | 84 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Maravai LifeSciences Holdings | 416 |
| Maze Therapeutics | 141 |
| Absci | 140 |
| MapLight Therapeutics | 133 |
| Septerna | 130 |
ZBIO News
- 10 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Zenas BioPharma Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 16 days ago - Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire
- 25 days ago - Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine - GlobeNewsWire
- 26 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 4 weeks ago - Zenas BioPharma submits BLA to FDA for obexelimab - TheFly
- 4 weeks ago - Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - GlobeNewsWire